Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DNDi Adds Affordable Ravidasvir Combo To Asian HCV Trials

This article was originally published in PharmAsia News

Executive Summary

DNDi is progressing its five-year initiative to improve access to affordable combination therapies for hepatitis C through new agreements for ravidasvir, which will be tested in trials in Malaysia and Thailand.

Advertisement

Related Content

Medicines Patent Pool Expands From HIV To Hepatitis C & TB, With 100 Projects On The Go

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC089435

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel